7 results about "Harmine" patented technology

The invention relates to the technical field of medicinal chemistry and parasitic disease prevention and treatment, and particularly discloses a novel harmine derivative, a synthesis method and application of the novel harmine derivative to toxoplasma gondii disease resistance. The structural general formula of the derivative is shown in the specification. Wherein R1 is selected from one of hydrogen, C1-4 alkyl, substituted or non-substituted five-membered aryl or six-membered aryl, and substituted or non-substituted five-membered heteroaryl or six-membered heteroaryl containing 1 to 4 heteroatoms selected from N, O or S; r9 is selected from one of hydrogen, substituted or unsubstituted five-membered aryl or six-membered aryl; and R7 is selected from hydrogen, C1-4 alkyl, substituted or unsubstituted five-membered aryl or six-membered aryl. Preferably, the compound is 1-methyl-9-(3-methylpyridine)-beta-carboline-7-ol, and the formula is shown in the description. The novel harmine derivative provided by the invention shows high-efficiency and low-toxicity anti-toxoplasma gondii activity, the synthesis method is simple, and an excellent candidate compound is provided for developing novel anti-toxoplasma gondii drugs.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The invention discloses a natural compound for inhibiting disulfide death by taking VAV3 as a target spot and application of the natural compound. Belongs to the technical field of biological medicine and pharmacy. According to the invention, through virtual screening and surface plasmon resonance technologies, seven small molecular compounds, including kaempferol, liensinine, sophocarpidine, isorhamnetin, deoxyshikonin, harmine and potenoside, which can be specifically bound with VAV3 protein are screened from a natural product library for the first time. In a C2C12 cell insulin resistance model, the compounds can significantly reduce the cell death rate caused by disulfide death, and the action mechanism of the compounds is to improve the activity or expression of VAV3, inhibit abnormal accumulation of cystine and improve the NADPH level, thereby effectively preventing disulfide bond crosslinking and collapse of an actin filament network. Experiments show that the compound provided by the invention can effectively inhibit disulfide death of skeletal muscle cells by targeting VAV3, and a new lead compound and a solution are provided for developing drugs for treating diabetic muscle dysfunction and related metabolic diseases.

The present invention relates to a pharmaceutical composition comprising (a) harmine or a pharmaceutically acceptable salt thereof; and (b) N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the w / w ratio of harmine to N,N-dimethyltryptamine is from 1.2 to 1.4, as well as to a kit of parts comprising (a) harmine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; and (b) N,N- dimethyltryptamine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein the w / w ratio of harmine to N,N-dimethyltryptamine is from 1.2 to 1.4. The pharmaceutical compositions of the present invention and the kits of parts of the present invention are particularly useful in treating and or preventing psychiatric, psychosomatic or somatic disorders.

The present application relates to the application of harmine in the preparation of a drug for treating CCNE1 amplified ovarian cancer. The cell line of the CCNE1 amplified ovarian cancer is selected from the SKOV3 cell line, the HEY cell line, the A2780 cell line, the OVCAR8 cell line or the OVCAR3 cell line. The present application finds that harmine has significant specific toxicity to CCNE1 amplified ovarian cancer cells. Cell experiments find that the IC50 value of harmine in CCNE1 high expression ovarian cancer cells is significantly lower than that in CCNE1 low expression ovarian cancer cells. Therefore, Haimine can specifically kill CCNE1 amplified ovarian cancer cells, and is expected to become a precise treatment drug for CCNE1 amplified ovarian cancer.

The present invention relates to a composition comprising harmine and (i) an uronic acid or (ii) a carboxylic acid and a monosaccharide, to a salt of harmine and uronic acid, to a kit of parts comprising (a) the composition or the salt of the invention and a pharmaceutically acceptable carrier and (b) DMT or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, to a pharmaceutical composition comprising the composition or the salt of the invention and a pharmaceutically acceptable carrier. The compositions, the salts, the kits of parts and the pharmaceutical compositions of the present invention are particularly useful in the treatment of psychiatric, psychosomatic or somatic disorders.